IMPACT OF GUT MICROBIOTA ON COLORECTAL CARCINOGENESIS AND OPPORTUNITIES FOR THERAPEUTIC MODULATION
DOI:
https://doi.org/10.31435/ijitss.1(49).2026.4884Keywords:
Colorectal Cancer, Dysbiosis, Fecal Microbiota Transplantation, Gut Microbiota, Microbiota-Targeted TherapyAbstract
Background: Colorectal cancer is a significant global health concern, characterized by increasing incidence and mortality rates, including among younger demographics. Emerging evidence highlights the role of gut microbiota in CRC development, progression, and response to the therapy.
Methodology: A narrative review was conducted, incorporating recent preclinical studies, clinical trials, cohort studies, and meta-analyses to examine the relationship between gut microbiota composition, metabolites, and colorectal cancer, as well as microbiota-targeted therapeutic strategies.
Results: Colorectal cancer is linked to intestinal dysbiosis, where pro-carcinogenic bacteria (Fusobacterium nucleatum, Bacteroides fragilis) are enriched and beneficial butyrate-producing bacteria (Faecalibacterium, Roseburia, Bifidobacterium) depleted. This leads to impaired short-chain fatty acid production, chronic inflammation, epithelial barrier disruption, and immune and oncogenic pathway modulation. Metagenomic and metabolomic analyses have identified microbial and metabolite signatures that could be useful for early detection, prognosis and predicting therapy response. A plethora of microbiota-targeted interventions have demonstrated promising preclinical and early clinical results, including dietary modulation, probiotics, prebiotics, postbiotics, fecal microbiota transplantation, and emerging strategies such as bacteriophage therapy. These interventions have been shown to improve antitumor immunity, reduce treatment-related toxicity, and potentially enhance therapeutic efficacy. Nevertheless, the presence of inter-study heterogeneity and the paucity of large-scale clinical validation currently serve as significant constraints on their routine implementation.
Conclusions: The gut microbiota represents a promising avenue for precision oncology in colorectal cancer. While preclinical and translational studies suggest potential for microbiota-based diagnostics, prognostics, and therapeutic modulation, well-designed, large-scale clinical trials are required to establish efficacy, safety, and standardized implementation.
References
Ajab, S. M., Zoughbor, S. H., Labania, L. A., Östlundh, L. M., Orsud, H. S., Olanda, M. A., Alkaabi, O., Alkuwaiti, S. H., Alnuaimi, S. M., & Al Rasbi, Z. (2024). Microbiota composition effect on immunotherapy outcomes in colorectal cancer patients: A systematic review. PLOS ONE, 19(7), e0307639. https://doi.org/10.1371/journal.pone.0307639
Alexander, J. L., Posma, J. M., Scott, A., Poynter, L., Mason, S. E., Doria, M. L., Herendi, L., Roberts, L., McDonald, J. A. K., Cameron, S., Hughes, D. J., Liska, V., Susova, S., Soucek, P., der Sluis, V. H., Gomez-Romero, M., Lewis, M. R., Hoyles, L., Woolston, A., et al. (2023). Pathobionts in the tumour microbiota predict survival following resection for colorectal cancer. Microbiome, 11(1), 100. https://doi.org/10.1186/s40168-023-01518-w
Alvandi, E., Wong, W. K. M., Joglekar, M. V., Spring, K. J., & Hardikar, A. A. (2022). Short-chain fatty acid concentrations in the incidence and risk-stratification of colorectal cancer: A systematic review and meta-analysis. BMC Medicine, 20(1), 323. https://doi.org/10.1186/s12916-022-02529-4
Avuthu, N., & Guda, C. (2022). Meta-analysis of altered gut microbiota reveals microbial and metabolic biomarkers for colorectal cancer. Microbiology Spectrum, 10(4). https://doi.org/10.1128/spectrum.00013-22
Bai, B., Ma, J., Xu, W., Chen, X., Chen, X., Lv, C., Su, W., Li, Y., Sun, H., Zhang, B., Xiang, D., Li, Z., Wu, Y., Sun, J., & Yin, M. (2025). Gut microbiota and colorectal cancer: Mechanistic insights, diagnostic advances, and microbiome-based therapeutic strategies. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1699893
Bartolomaeus, T. U. P., Birkner, T., Bartolomaeus, H., Löber, U., Avery, E. G., Mähler, A., Weber, D., Kochlik, B., Balogh, A., Wilck, N., Boschmann, M., Müller, D. N., Markó, L., & Forslund, S. K. (2021). Quantifying technical confounders in microbiome studies. Cardiovascular Research, 117(3), 863–875. https://doi.org/10.1093/cvr/cvaa128
Bender, C., Zipeto, D., Bidoia, C., Costantini, S., Zamò, A., Menestrina, F., & Bertazzoni, U. (2009). Analysis of colorectal cancers for human cytomegalovirus presence. Infectious Agents and Cancer, 4(1), 6. https://doi.org/10.1186/1750-9378-4-6
Bohm, M. S., Ramesh, A. V., Pierre, J. F., Cook, K. L., Murphy, E. A., & Makowski, L. (2024). Fecal microbial transplants as investigative tools in cancer. American Journal of Physiology-Gastrointestinal and Liver Physiology, 327(5), G711–G726. https://doi.org/10.1152/ajpgi.00171.2024
Borozan, I., Zaidi, S. H., Harrison, T. A., Phipps, A. I., Zheng, J., Lee, S., Trinh, Q. M., Steinfelder, R. S., Adams, J., Banbury, B. L., Berndt, S. I., Brezina, S., Buchanan, D. D., Bullman, S., Cao, Y., Farris, A. B., Figueiredo, J. C., Giannakis, M., Heisler, L. E., et al. (2022). Molecular and pathology features of colorectal tumors and patient outcomes are associated with Fusobacterium nucleatum and its subspecies animalis. Cancer Epidemiology, Biomarkers & Prevention, 31(1), 210–220. https://doi.org/10.1158/1055-9965.EPI-21-0463
Brusnic, O., Onisor, D., Boicean, A., Hasegan, A., Ichim, C., Guzun, A., Chicea, R., Todor, S. B., Vintila, B. I., Anderco, P., Porr, C., Dura, H., Fleaca, S. R., & Cristian, A. N. (2024). Fecal microbiota transplantation: Insights into colon carcinogenesis and immune regulation. Journal of Clinical Medicine, 13(21). https://doi.org/10.3390/jcm13216578
Cao, Q., Yang, M., & Chen, M. (2025). Metabolic interactions: How gut microbial metabolites influence colorectal cancer. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1611698
Carding, S., Verbeke, K., Vipond, D. T., Corfe, B. M., & Owen, L. J. (2015). Dysbiosis of the gut microbiota in disease. Microbial Ecology in Health & Disease, 26(0). https://doi.org/10.3402/mehd.v26.26191
Celiberto, F., Aloisio, A., Girardi, B., Pricci, M., Iannone, A., Russo, F., Riezzo, G., D’Attoma, B., Ierardi, E., Losurdo, G., & Di Leo, A. (2023). Fibres and colorectal cancer: Clinical and molecular evidence. International Journal of Molecular Sciences, 24(17), 13501. https://doi.org/10.3390/ijms241713501
Chang, C.-W., Lee, H.-C., Li, L.-H., Chiang Chiau, J.-S., Wang, T.-E., Chuang, W.-H., Chen, M.-J., Wang, H.-Y., Shih, S.-C., Liu, C.-Y., Tsai, T.-H., & Chen, Y.-J. (2020). Fecal microbiota transplantation prevents intestinal injury, upregulation of toll-like receptors, and 5-fluorouracil/oxaliplatin-induced toxicity in colorectal cancer. International Journal of Molecular Sciences, 21(2), 386. https://doi.org/10.3390/ijms21020386
Chen, C., Su, Q., Zi, M., Hua, X., & Zhang, Z. (2025). Harnessing gut microbiota for colorectal cancer therapy: From clinical insights to therapeutic innovations. NPJ Biofilms and Microbiomes, 11(1), 190. https://doi.org/10.1038/s41522-025-00818-3
Chen, F., Dai, X., Zhou, C.-C., Li, K., Zhang, Y., Lou, X.-Y., Zhu, Y.-M., Sun, Y.-L., Peng, B.-X., & Cui, W. (2022). Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma. Gut, 71(7), 1315–1325. https://doi.org/10.1136/gutjnl-2020-323476
Cheng, B., Feng, H., Li, C., Jia, F., & Zhang, X. (2025). The mutual effect of dietary fiber and polyphenol on gut microbiota: Implications for the metabolic and microbial modulation and associated health benefits. Carbohydrate Polymers, 358, 123541. https://doi.org/10.1016/j.carbpol.2025.123541
Cheng, J. Y., Sheu, L. F., Meng, C. L., Lee, W. H., & Lin, J. C. (1995). Detection of human papillomavirus DNA in colorectal carcinomas by polymerase chain reaction. Gut, 37(1), 87–90. https://doi.org/10.1136/gut.37.1.87
Chen, M., Hu, Y., Zhou, X., Xia, L., Wu, C., Chen, Y., & Feng, W. (2025). Microbial therapeutics for cancer: Emerging strategies and biomedical applications. Chemical Communications, 61(76), 14531–14564. https://doi.org/10.1039/D5CC03618F
Chen, M., Lin, W., Li, N., Wang, Q., Zhu, S., Zeng, A., & Song, L. (2022). Therapeutic approaches to colorectal cancer via strategies based on modulation of gut microbiota. Frontiers in Microbiology, 13. https://doi.org/10.3389/fmicb.2022.945533
Coker, O. O., Liu, C., Wu, W. K. K., Wong, S. H., Jia, W., Sung, J. J. Y., & Yu, J. (2022). Altered gut metabolites and microbiota interactions are implicated in colorectal carcinogenesis and can be non-invasive diagnostic biomarkers. Microbiome, 10(1), 35. https://doi.org/10.1186/s40168-021-01208-5
Cruz, B. C. S., Sarandy, M. M., Messias, A. C., Gonçalves, R. V., Ferreira, C. L. L. F., & Peluzio, M. C. G. (2020). Preclinical and clinical relevance of probiotics and synbiotics in colorectal carcinogenesis: A systematic review. Nutrition Reviews, 78(8), 667–687. https://doi.org/10.1093/nutrit/nuz087
Dadgar-Zankbar, L., Elahi, Z., Shariati, A., Khaledi, A., Razavi, S., & Khoshbayan, A. (2024). Exploring the role of Fusobacterium nucleatum in colorectal cancer: Implications for tumor proliferation and chemoresistance. Cell Communication and Signaling, 22(1), 547. https://doi.org/10.1186/s12964-024-01909-y
Dai, Z., Coker, O. O., Nakatsu, G., Wu, W. K. K., Zhao, L., Chen, Z., Chan, F. K. L., Kristiansen, K., Sung, J. J. Y., Wong, S. H., & Yu, J. (2018). Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome, 6(1), 70. https://doi.org/10.1186/s40168-018-0451-2
D’Amore, T., Zolfanelli, C., Lauciello, V., Di Ciancia, A., Vagliasindi, A., Smaoui, S., & Varzakas, T. (2025). Using postbiotics from functional foods for managing colorectal cancer: Mechanisms, sources, therapeutic potential, and clinical perspectives. Microorganisms, 13(6), 1335. https://doi.org/10.3390/microorganisms13061335
Dikeocha, I. J., Al-Kabsi, A. M., Eid, E. E. M., Hussin, S., & Alshawsh, M. A. (2021). Probiotics supplementation in patients with colorectal cancer: A systematic review of randomized controlled trials. Nutrition Reviews, 80(1), 22–49. https://doi.org/10.1093/nutrit/nuab006
Ding, X., Ting, N. L.-N., Wong, C. C., Huang, P., Bakuradze, N., Jiang, L., Liu, C., Lin, Y., Li, S., Liu, Y., Xie, M., Liu, W., Yuan, K., Wang, L., Zhang, X., Ding, Y., Li, Q., Sun, Y., Miao, Y., et al. (2025). Bacteroides fragilis promotes chemoresistance in colorectal cancer, and its elimination by phage VA7 restores chemosensitivity. Cell Host & Microbe, 33(6), 941–956.e10. https://doi.org/10.1016/j.chom.2025.05.004
Eng, C., & Hochster, H. (2021). Early-onset colorectal cancer: The mystery remains. JNCI: Journal of the National Cancer Institute, 113(12), 1608–1610. https://doi.org/10.1093/jnci/djab127
Eng, C., Yoshino, T., Ruíz-García, E., Mostafa, N., Cann, C. G., O’Brian, B., Benny, A., Perez, R. O., & Cremolini, C. (2024). Colorectal cancer. The Lancet, 404(10449), 294–310. https://doi.org/10.1016/S0140-6736(24)00360-X
Erfanian, N., Nasseri, S., Miraki Feriz, A., Safarpour, H., & Namaei, M. H. (2023). Characterization of Wnt signaling pathway under treatment of Lactobacillus acidophilus postbiotic in colorectal cancer using an integrated in silico and in vitro analysis. Scientific Reports, 13(1), 22988. https://doi.org/10.1038/s41598-023-50047-x
Fan, Y., & Pedersen, O. (2021). Gut microbiota in human metabolic health and disease. Nature Reviews Microbiology, 19(1), 55–71. https://doi.org/10.1038/s41579-020-0433-9
Feizi, H., Plotnikov, A., Rezaee, M. A., Ganbarov, K., Kamounah, F. S., Nikitin, S., Kadkhoda, H., Gholizadeh, P., Pagliano, P., & Kafil, H. S. (2024). Postbiotics versus probiotics in early-onset colorectal cancer. Critical Reviews in Food Science and Nutrition, 64(11), 3573–3582. https://doi.org/10.1080/10408398.2022.2132464
Feng, J., Gong, Z., Sun, Z., Li, J., Xu, N., Thorne, R. F., Zhang, X. D., Liu, X., & Liu, G. (2023). Microbiome and metabolic features of tissues and feces reveal diagnostic biomarkers for colorectal cancer. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1034325
Fong, W., Li, Q., & Yu, J. (2020). Gut microbiota modulation: A novel strategy for prevention and treatment of colorectal cancer. Oncogene, 39(26), 4925–4943. https://doi.org/10.1038/s41388-020-1341-1
Fusco, W., Bricca, L., Kaitsas, F., Tartaglia, M. F., Venturini, I., Rugge, M., Gasbarrini, A., Cammarota, G., & Ianiro, G. (2024). Gut microbiota in colorectal cancer: From pathogenesis to clinic. Best Practice & Research Clinical Gastroenterology, 72, 101941. https://doi.org/10.1016/j.bpg.2024.101941
Gao, R., Wu, C., Zhu, Y., Kong, C., Zhu, Y., Gao, Y., Zhang, X., Yang, R., Zhong, H., Xiong, X., Chen, C., Xu, Q., & Qin, H. (2022). Integrated analysis of colorectal cancer reveals cross-cohort gut microbial signatures and associated serum metabolites. Gastroenterology, 163(4), 1024–1037.e9. https://doi.org/10.1053/j.gastro.2022.06.069
García Mansilla, M. J., Rodríguez Sojo, M. J., Roxana Lista, A., Ayala Mosqueda, C. V., García García, J., Gálvez Peralta, J., Rodríguez Nogales, A., Ruiz Malagón, A. J., & Rodríguez Sánchez, M. J. (2025). Modulating strategies of the intestinal microbiota in colorectal cancer. Nutrients, 17(22), 3565. https://doi.org/10.3390/nu17223565
Garvey, M. (2024). Intestinal dysbiosis: Microbial imbalance impacts on colorectal cancer initiation, progression and disease mitigation. Biomedicines, 12(4). https://doi.org/10.3390/biomedicines12040740
Genua, F., Raghunathan, V., Jenab, M., Gallagher, W. M., & Hughes, D. J. (2021). The role of gut barrier dysfunction and microbiome dysbiosis in colorectal cancer development. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.626349
Ghorbani, E., Avan, A., Ryzhikov, M., Ferns, G., Khazaei, M., & Soleimanpour, S. (2022). Role of lactobacillus strains in the management of colorectal cancer: An overview of recent advances. Nutrition, 103–104, 111828. https://doi.org/10.1016/j.nut.2022.111828
Greenhalgh, K., Ramiro-Garcia, J., Heinken, A., Ullmann, P., Bintener, T., Pacheco, M. P., Baginska, J., Shah, P., Frachet, A., Halder, R., Fritz, J. V., Sauter, T., Thiele, I., Haan, S., Letellier, E., & Wilmes, P. (2019). Integrated in vitro and in silico modeling delineates the molecular effects of a synbiotic regimen on colorectal-cancer-derived cells. Cell Reports, 27(5), 1621–1632.e9. https://doi.org/10.1016/j.celrep.2019.04.001
Gurbatri, C. R., Radford, G. A., Vrbanac, L., Im, J., Thomas, E. M., Coker, C., Taylor, S. R., Jang, Y., Sivan, A., Rhee, K., Saleh, A. A., Chien, T., Zandkarimi, F., Lia, I., Lannagan, T. R. M., Wang, T., Wright, J. A., Kobayashi, H., Ng, J. Q., et al. (2024). Engineering tumor-colonizing E. coli Nissle 1917 for detection and treatment of colorectal neoplasia. Nature Communications, 15(1), 646. https://doi.org/10.1038/s41467-024-44776-4
Hamidi Nia, L., & Claesen, J. (2022). Engineered cancer targeting microbes and encapsulation devices for human gut microbiome applications. Biochemistry, 61(24), 2841–2848. https://doi.org/10.1021/acs.biochem.2c00251
Ha, S., Zhang, X., & Yu, J. (2024). Probiotics intervention in colorectal cancer: From traditional approaches to novel strategies. Chinese Medical Journal, 137(1), 8–20. https://doi.org/10.1097/CM9.0000000000002955
Herlo, L.-F., Salcudean, A., Sirli, R., Iurciuc, S., Herlo, A., Nelson-Twakor, A., Alexandrescu, L., & Dumache, R. (2024). Gut microbiota signatures in colorectal cancer as a potential diagnostic biomarker in the future: A systematic review. International Journal of Molecular Sciences, 25(14), 7937. https://doi.org/10.3390/ijms25147937
He, Y., Peng, K., Tan, J., Hao, Y., Zhang, S., Gao, C., & Li, L. (2025). Short-chain fatty acids and colorectal cancer: A systematic review and integrative Bayesian meta-analysis of microbiome–metabolome interactions and intervention efficacy. Nutrients, 17(22), 3552. https://doi.org/10.3390/nu17223552
Hsu, C.-Y., Polatova, D., Hamad, R. H., Patel, P. N., Akram, M., Singh, G., Arora, V., Nayak, P. P., Kadhem, M., & Hamzah, H. F. (2026). Phage therapy in cancer treatment: Mechanisms, emerging innovations, and translational progress. Critical Reviews in Oncology/Hematology, 218, 105085. https://doi.org/10.1016/j.critrevonc.2025.105085
Huang, F., Li, S., Chen, W., Han, Y., Yao, Y., Yang, L., Li, Q., Xiao, Q., Wei, J., Liu, Z., Chen, T., & Deng, X. (2023). Postoperative probiotics administration attenuates gastrointestinal complications and gut microbiota dysbiosis caused by chemotherapy in colorectal cancer patients. Nutrients, 15(2), 356. https://doi.org/10.3390/nu15020356
Huangfu, S., Zhang, W., Zhang, H., Li, Y., Zhang, Y., Nie, J., Chu, X., Chen, C., Jiang, H., & Pan, J. (2021). Clinicopathological and prognostic significance of Fusobacterium nucleatum infection in colorectal cancer: A meta-analysis. Journal of Cancer, 12(6), 1583–1591. https://doi.org/10.7150/jca.50111
Huh, H., Chen, D.-W., Foldvari, M., Slavcev, R., & Blay, J. (2022). EGFR-targeted bacteriophage lambda penetrates model stromal and colorectal carcinoma tissues, is taken up into carcinoma cells, and interferes with 3-dimensional tumor formation. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.957233
Hu, R., Qiu, Y., Liu, D., Chen, S., Chen, K., Xu, Y., Yuan, J., Zhang, X., & Li, X. (2025). Advances in intestinal flora for the development, diagnosis and treatment of CRC. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1495274
Hussain, M. B., Albukhari, A. F., Rafeeq, M., Imran, M., Albagholi, A. H., & Assedoodi, M. A. (2025). Anticancer potential of dietary fiber for colorectal carcinoma: A narrative review. Annals of Medicine, 57(1). https://doi.org/10.1080/07853890.2025.2583756
Incognito, D., Ciappina, G., Gelsomino, C., Picone, A., Consolo, P., Scano, A., Franchina, T., Maurea, N., Quagliariello, V., Berretta, S., Ottaiano, A., & Berretta, M. (2025). Fusobacterium nucleatum in colorectal cancer: Relationship among immune modulation, potential biomarkers and therapeutic implications. International Journal of Molecular Sciences, 26(19), 9710. https://doi.org/10.3390/ijms26199710
John Kenneth, M., Tsai, H.-C., Fang, C.-Y., Hussain, B., Chiu, Y.-C., & Hsu, B.-M. (2023). Diet-mediated gut microbial community modulation and signature metabolites as potential biomarkers for early diagnosis, prognosis, prevention and stage-specific treatment of colorectal cancer. Journal of Advanced Research, 52, 45–57. https://doi.org/10.1016/j.jare.2022.12.015
Kang, X., Ng, S.-K., Liu, C., Lin, Y., Zhou, Y., Kwong, T. N. Y., Ni, Y., Lam, T. Y. T., Wu, W. K. K., Wei, H., Sung, J. J. Y., Yu, J., & Wong, S. H. (2023). Altered gut microbiota of obesity subjects promotes colorectal carcinogenesis in mice. EBioMedicine, 93, 104670. https://doi.org/10.1016/j.ebiom.2023.104670
Karam, F., El Deghel, Y., Iratni, R., Dakroub, A. H., & Eid, A. H. (2025). The gut microbiome and colorectal cancer: An integrative review of the underlying mechanisms. Cell Biochemistry and Biophysics, 83(3), 2637–2650. https://doi.org/10.1007/s12013-025-01683-9
Keohane, D. M., Ghosh, T. S., Jeffery, I. B., Molloy, M. G., O’Toole, P. W., & Shanahan, F. (2020). Microbiome and health implications for ethnic minorities after enforced lifestyle changes. Nature Medicine, 26(7), 1089–1095. https://doi.org/10.1038/s41591-020-0963-8
Kudra, A., Kaźmierczak-Siedlecka, K., Sobocki, B. K., Muszyński, D., Połom, J., Carbone, L., Marano, L., Roviello, F., Kalinowski, L., & Stachowska, E. (2023). Postbiotics in oncology: Science or science fiction? Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1182547
Kvakova, M., Kamlarova, A., Stofilova, J., Benetinova, V., & Bertkova, I. (2022). Probiotics and postbiotics in colorectal cancer: Prevention and complementary therapy. World Journal of Gastroenterology, 28(27), 3370–3382. https://doi.org/10.3748/wjg.v28.i27.3370
Lee, D.-W., Han, S.-W., Kang, J.-K., Bae, J. M., Kim, H.-P., Won, J.-K., Jeong, S.-Y., Park, K. J., Kang, G. H., & Kim, T.-Y. (2018). Association between Fusobacterium nucleatum, pathway mutation, and patient prognosis in colorectal cancer. Annals of Surgical Oncology, 25(11), 3389–3395. https://doi.org/10.1245/s10434-018-6681-5
Li, B., Wei, Z., Wang, Z., Xu, F., Yang, J., Lin, B., Chen, Y., Wenren, H., Wu, L., Guo, X., Liu, Y., & Wei, Y. (2024). Fusobacterium nucleatum induces oxaliplatin resistance by inhibiting ferroptosis through E-cadherin/β-catenin/GPX4 axis in colorectal cancer. Free Radical Biology and Medicine, 220, 125–138. https://doi.org/10.1016/j.freeradbiomed.2024.04.226
Li, J., Zhang, A., Wu, F., & Wang, X. (2022). Alterations in the gut microbiota and their metabolites in colorectal cancer: Recent progress and future prospects. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.841552
Lin, Y., Lau, H. C.-H., Liu, Y., Kang, X., Wang, Y., Ting, N. L.-N., Kwong, T. N.-Y., Han, J., Liu, W., Liu, C., She, J., Wong, S. H., Sung, J. J.-Y., & Yu, J. (2022). Altered mycobiota signatures and enriched pathogenic Aspergillus rambellii are associated with colorectal cancer based on multicohort fecal metagenomic analyses. Gastroenterology, 163(4), 908–921. https://doi.org/10.1053/j.gastro.2022.06.038
Li, Q., Liu, D., Liang, M., Zhu, Y., Yousaf, M., & Wu, Y. (2024). Mechanism of probiotics in the intervention of colorectal cancer: A review. World Journal of Microbiology and Biotechnology, 40(10), 306. https://doi.org/10.1007/s11274-024-04112-w
Liu, J., Dong, W., Zhao, J., Wu, J., Xia, J., Xie, S., & Song, X. (2022). Gut microbiota profiling variated during colorectal cancer development in mouse. BMC Genomics, 23(S4), 848. https://doi.org/10.1186/s12864-022-09008-3
Liu, Y.-H., Chen, J., Chen, X., & Liu, H. (2024). Factors of faecal microbiota transplantation applied to cancer management. Journal of Drug Targeting, 32(2), 101–114. https://doi.org/10.1080/1061186X.2023.2299724
Lynch, S. V., & Pedersen, O. (2016). The human intestinal microbiome in health and disease. New England Journal of Medicine, 375(24), 2369–2379. https://doi.org/10.1056/NEJMra1600266
Madrigal-Matute, J., & Bañón-Escandell, S. (2023). Colorectal cancer and microbiota modulation for clinical use: A systematic review. Nutrition and Cancer, 75(1), 123–139. https://doi.org/10.1080/01635581.2022.2108468
Mahdavi, M., Laforest-Lapointe, I., & Massé, E. (2021). Preventing colorectal cancer through prebiotics. Microorganisms, 9(6), 1325. https://doi.org/10.3390/microorganisms9061325
Matsumoto, H., Gu, T., Yo, S., Sasahira, M., Monden, S., Ninomiya, T., Osawa, M., Handa, O., Umegaki, E., & Shiotani, A. (2025). Fecal microbiota transplantation using donor stool obtained from exercised mice suppresses colonic tumor development induced by azoxymethane in high-fat diet-induced obese mice. Microorganisms, 13(5), 1009. https://doi.org/10.3390/microorganisms13051009
Meng, S., Liu, C., Zhang, K., Li, J., Wang, D., Zhao, J., Wang, Y., Du, M., Li, C., Wang, Y., Lu, W., & Zhu, Y. (2025). A prebiotic-supplemented formula improves gut microbiota and intestinal inflammatory microenvironment in patients with colorectal adenoma: A double-blind, placebo-controlled trial. The Journal of Nutrition, 155(11), 3924–3937. https://doi.org/10.1016/j.tjnut.2025.09.005
Mima, K., Nishihara, R., Qian, Z. R., Cao, Y., Sukawa, Y., Nowak, J. A., Yang, J., Dou, R., Masugi, Y., Song, M., Kostic, A. D., Giannakis, M., Bullman, S., Milner, D. A., Baba, H., Giovannucci, E. L., Garraway, L. A., Freeman, G. J., Dranoff, G., ... Ogino, S. (2016). Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut, 65(12), 1973–1980. https://doi.org/10.1136/gutjnl-2015-310101
Nakatsu, G., Li, X., Zhou, H., Sheng, J., Wong, S. H., Wu, W. K. K., Ng, S. C., Tsoi, H., Dong, Y., Zhang, N., He, Y., Kang, Q., Cao, L., Wang, K., Zhang, J., Liang, Q., Yu, J., & Sung, J. J. Y. (2015). Gut mucosal microbiome across stages of colorectal carcinogenesis. Nature Communications, 6(1), 8727. https://doi.org/10.1038/ncomms9727
Niechcial, A., Schwarzfischer, M., Wawrzyniak, P., Determann, M., Pöhlmann, D., Wawrzyniak, M., Gueguen, E., Walker, M. R., Morsy, Y., Atrott, K., Wilmink, M., Linzmeier, L., Spalinger, M. R., Holowacz, S., Leblanc, A., & Scharl, M. (2025). Probiotic administration modulates gut microbiota and suppresses tumor growth in murine models of colorectal cancer. International Journal of Molecular Sciences, 26(9), 4404. https://doi.org/10.3390/ijms26094404
Ooi, V. Y., & Yeh, T.-Y. (2024). Recent advances and mechanisms of phage-based therapies in cancer treatment. International Journal of Molecular Sciences, 25(18), 9938. https://doi.org/10.3390/ijms25189938
Pedrosa, L. de F., & Fabi, J. P. (2024). Dietary fiber as a wide pillar of colorectal cancer prevention and adjuvant therapy. Critical Reviews in Food Science and Nutrition, 64(18), 6177–6197. https://doi.org/10.1080/10408398.2022.2164245
Perillo, F., Amoroso, C., Strati, F., Giuffrè, M. R., Díaz-Basabe, A., Lattanzi, G., & Facciotti, F. (2020). Gut microbiota manipulation as a tool for colorectal cancer management: Recent advances in its use for therapeutic purposes. International Journal of Molecular Sciences, 21(15), 5389. https://doi.org/10.3390/ijms21155389
Piccinno, G., Thompson, K. N., Manghi, P., Ghazi, A. R., Thomas, A. M., Blanco-Míguez, A., Asnicar, F., Mladenovic, K., Pinto, F., Armanini, F., Punčochář, M., Piperni, E., Heidrich, V., Fackelmann, G., Ferrero, G., Tarallo, S., Nguyen, L. H., Yan, Y., Keles, N. A., ... Segata, N. (2025). Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancer. Nature Medicine, 31(7), 2416–2429. https://doi.org/10.1038/s41591-025-03693-9
Rad, A. H., Aghebati-Maleki, L., Kafil, H. S., & Abbasi, A. (2021). Molecular mechanisms of postbiotics in colorectal cancer prevention and treatment. Critical Reviews in Food Science and Nutrition, 61(11), 1787–1803. https://doi.org/10.1080/10408398.2020.1765310
Roshandel, G., Ghasemi-Kebria, F., & Malekzadeh, R. (2024). Colorectal cancer: Epidemiology, risk factors, and prevention. Cancers, 16(8), 1530. https://doi.org/10.3390/cancers16081530
Salvucci, M., Crawford, N., Stott, K., Bullman, S., Longley, D. B., & Prehn, J. H. M. (2021). Patients with mesenchymal tumours and high Fusobacteriales prevalence have worse prognosis in colorectal cancer (CRC). Gut. https://doi.org/10.1136/gutjnl-2021-325193
Sánchez-Alcoholado, L., Laborda-Illanes, A., Otero, A., Ordóñez, R., González-González, A., Plaza-Andrades, I., Ramos-Molina, B., Gómez-Millán, J., & Queipo-Ortuño, M. I. (2021). Relationships of gut microbiota composition, short-chain fatty acids and polyamines with the pathological response to neoadjuvant radiochemotherapy in colorectal cancer patients. International Journal of Molecular Sciences, 22(17), 9549. https://doi.org/10.3390/ijms22179549
Sánchez-Alcoholado, L., Ramos-Molina, B., Otero, A., Laborda-Illanes, A., Ordóñez, R., Medina, J. A., Gómez-Millán, J., & Queipo-Ortuño, M. I. (2020). The role of the gut microbiome in colorectal cancer development and therapy response. Cancers, 12(6), 1406. https://doi.org/10.3390/cancers12061406
Serna, G., Ruiz-Pace, F., Hernando, J., Alonso, L., Fasani, R., Landolfi, S., Comas, R., Jimenez, J., Elez, E., Bullman, S., Tabernero, J., Capdevila, J., Dienstmann, R., & Nuciforo, P. (2020). Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Annals of Oncology, 31(10), 1366–1375. https://doi.org/10.1016/j.annonc.2020.06.003
Song, Q., Gao, Y., Liu, K., Tang, Y., Man, Y., & Wu, H. (2024). Gut microbial and metabolomics profiles reveal the potential mechanism of fecal microbiota transplantation in modulating the progression of colitis-associated colorectal cancer in mice. Journal of Translational Medicine, 22(1), 1028. https://doi.org/10.1186/s12967-024-05786-4
Taghinezhad-S, S., Mohseni, A. H., & Fu, X. (2021). Intervention on gut microbiota may change the strategy for management of colorectal cancer. Journal of Gastroenterology and Hepatology, 36(6), 1508–1517. https://doi.org/10.1111/jgh.15369
Ternes, D., Karta, J., Tsenkova, M., Wilmes, P., Haan, S., & Letellier, E. (2020). Microbiome in colorectal cancer: How to get from meta-omics to mechanism? Trends in Microbiology, 28(5), 401–423. https://doi.org/10.1016/j.tim.2020.01.001
Tudorache, M., Treteanu, A.-R., Gradisteanu Pircalabioru, G., Lixandru-Petre, I.-O., Bolocan, A., & Andronic, O. (2025). Gut microbiome alterations in colorectal cancer: Mechanisms, therapeutic strategies, and precision oncology perspectives. Cancers, 17(14), 2294. https://doi.org/10.3390/cancers17142294
Upadhyay, U., Dhar, E., Bomrah, S., & Syed-Abdul, S. (2025). Unraveling the role of gut microbiota in colorectal cancer: A global perspectives and biomarkers as early screening tool for colorectal cancer. https://doi.org/10.3233/SHTI251018
Van Dingenen, L., Segers, C., Wouters, S., Mysara, M., Leys, N., Kumar-Singh, S., Malhotra-Kumar, S., & Van Houdt, R. (2023). Dissecting the role of the gut microbiome and fecal microbiota transplantation in radio- and immunotherapy treatment of colorectal cancer. Frontiers in Cellular and Infection Microbiology, 13. https://doi.org/10.3389/fcimb.2023.1298264
Vrzáčková, N., Ruml, T., & Zelenka, J. (2021). Postbiotics, metabolic signaling, and cancer. Molecules, 26(6), 1528. https://doi.org/10.3390/molecules26061528
Wang, X., Huang, Y., Yang, Z., Yang, Y., Wei, F., Yan, M., Li, F., & Wang, C. (2025). Effect of probiotics combined with immune checkpoint suppressors and chemotherapeutic agents on digestive system function, intestinal immunity and prognosis in patients with metastatic colorectal carcinoma: A quasi-experimental study. BMC Gastroenterology, 25(1), 38. https://doi.org/10.1186/s12876-025-03604-9
Wang, Y., & Li, H. (2022). Gut microbiota modulation: A tool for the management of colorectal cancer. Journal of Translational Medicine, 20(1), 178. https://doi.org/10.1186/s12967-022-03378-8
Wekking, D., van den Ende, T., Bijlsma, M. F., Vidal-Itriago, A., Nieuwdorp, M., & van Laarhoven, H. W. M. (2025). Fecal microbiota transplantation to enhance cancer treatment outcomes across different cancer types: A systematic literature review. Cancer Treatment Reviews, 140, 103025. https://doi.org/10.1016/j.ctrv.2025.103025
Weston, A., & Harris, C. C. (2003). Multistage carcinogenesis. In D. W. Kufe, R. E. Pollock, R. R. Weichselbaum, et al. (Eds.), Holland-Frei cancer medicine (6th ed.). BC Decker. https://www.ncbi.nlm.nih.gov/books/NBK13982/
Wierzbicka, A., Mańkowska-Wierzbicka, D., Mardas, M., & Stelmach-Mardas, M. (2021). Role of probiotics in modulating human gut microbiota populations and activities in patients with colorectal cancer—A systematic review of clinical trials. Nutrients, 13(4), 1160. https://doi.org/10.3390/nu13041160
Wong, C. C., & Yu, J. (2023). Gut microbiota in colorectal cancer development and therapy. Nature Reviews Clinical Oncology, 20(7), 429–452. https://doi.org/10.1038/s41571-023-00766-x
Xie, W., Zhong, Y.-S., Li, X.-J., Kang, Y.-K., Peng, Q.-Y., & Ying, H.-Z. (2024). Postbiotics in colorectal cancer: Intervention mechanisms and perspectives. Frontiers in Microbiology, 15. https://doi.org/10.3389/fmicb.2024.1360225
Xu, H., Cao, C., Ren, Y., Weng, S., Liu, L., Guo, C., Wang, L., Han, X., Ren, J., & Liu, Z. (2022). Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.949490
Yachida, S., Mizutani, S., Shiroma, H., Shiba, S., Nakajima, T., Sakamoto, T., Watanabe, H., Masuda, K., Nishimoto, Y., Kubo, M., Hosoda, F., Rokutan, H., Matsumoto, M., Takamaru, H., Yamada, M., Matsuda, T., Iwasaki, M., Yamaji, T., Yachida, T., ... Yamada, T. (2019). Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nature Medicine, 25(6), 968–976. https://doi.org/10.1038/s41591-019-0458-7
Yadegar, A., Bar-Yoseph, H., Monaghan, T. M., Pakpour, S., Severino, A., Kuijper, E. J., Smits, W. K., Terveer, E. M., Neupane, S., Nabavi-Rad, A., Sadeghi, J., Cammarota, G., Ianiro, G., Nap-Hill, E., Leung, D., Wong, K., & Kao, D. (2024). Fecal microbiota transplantation: Current challenges and future landscapes. Clinical Microbiology Reviews, 37(2). https://doi.org/10.1128/cmr.00060-22
Yang, M., Wang, L., Luo, C., Shang, J., Zheng, X., Qian, J., & Yang, R. (2025). Efficacy and safety of probiotics in preventing chemotherapy-related diarrhea in patients with colorectal cancer: A systematic review and meta-analysis based on 18 randomized trials. Medicine, 104(27), e43126. https://doi.org/10.1097/MD.0000000000043126
Yang, Y.-C., Chang, S.-C., Hung, C.-S., Shen, M.-H., Lai, C.-L., & Huang, C.-J. (2025). Gut-microbiota-derived metabolites and probiotic strategies in colorectal cancer: Implications for disease modulation and precision therapy. Nutrients, 17(15), 2501. https://doi.org/10.3390/nu17152501
Yang, Y., Du, L., Shi, D., Kong, C., Liu, J., Liu, G., Li, X., & Ma, Y. (2021). Dysbiosis of human gut microbiome in young-onset colorectal cancer. Nature Communications, 12(1), 6757. https://doi.org/10.1038/s41467-021-27112-y
Yao, B., Wei, W., & Zhang, H. (2025). Efficacy of probiotics or synbiotics supplementation on chemotherapy-induced complications and gut microbiota dysbiosis in gastrointestinal cancer: A systematic review and meta-analysis. European Journal of Clinical Nutrition, 79(7), 616–626. https://doi.org/10.1038/s41430-024-01542-5
Yi, Y., Shen, L., Shi, W., Xia, F., Zhang, H., Wang, Y., Zhang, J., Wang, Y., Sun, X., Zhang, Z., Zou, W., Yang, W., Zhang, L., Zhu, J., Goel, A., Ma, Y., & Zhang, Z. (2021). Gut microbiome components predict response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: A prospective, longitudinal study. Clinical Cancer Research, 27(5), 1329–1340. https://doi.org/10.1158/1078-0432.CCR-20-3445
Yu, H., Li, X.-X., Han, X., Chen, B.-X., Zhang, X.-H., Gao, S., Xu, D.-Q., Wang, Y., Gao, Z.-K., Yu, L., Zhu, S.-L., Yao, L.-C., Liu, G.-R., Liu, S.-L., & Mu, X.-Q. (2023). Fecal microbiota transplantation inhibits colorectal cancer progression: Reversing intestinal microbial dysbiosis to enhance anti-cancer immune responses. Frontiers in Microbiology, 14. https://doi.org/10.3389/fmicb.2023.1126808
Yu, L., Zhao, G., Wang, L., Zhou, X., Sun, J., Li, X., Zhu, Y., He, Y., Kofonikolas, K., Bogaert, D., Dunlop, M., Zhu, Y., Theodoratou, E., & Li, X. (2022). A systematic review of microbial markers for risk prediction of colorectal neoplasia. British Journal of Cancer, 126(9), 1318–1328. https://doi.org/10.1038/s41416-022-01740-7
Zhang, J., Wei, Z.-J., & Fan, G. (2025). Emerging understanding of gut microbiome in colorectal cancer and food-related intervention strategies. Foods, 14(17), 3040. https://doi.org/10.3390/foods14173040
Zhao, L.-Y., Mei, J.-X., Yu, G., Lei, L., Zhang, W.-H., Liu, K., Chen, X.-L., Kołat, D., Yang, K., & Hu, J.-K. (2023). Role of the gut microbiota in anticancer therapy: From molecular mechanisms to clinical applications. Signal Transduction and Targeted Therapy, 8(1), 201. https://doi.org/10.1038/s41392-023-01406-7
Zhao, Y., & Jiang, Q. (2021). Roles of the polyphenol–gut microbiota interaction in alleviating colitis and preventing colitis-associated colorectal cancer. Advances in Nutrition, 12(2), 546–565. https://doi.org/10.1093/advances/nmaa104
Zhong, M., Xiong, Y., Ye, Z., Zhao, J., Zhong, L., Liu, Y., Zhu, Y., Tian, L., Qiu, X., & Hong, X. (2020). Microbial community profiling distinguishes left-sided and right-sided colon cancer. Frontiers in Cellular and Infection Microbiology, 10. https://doi.org/10.3389/fcimb.2020.498502
Zou, S., Yang, C., Zhang, J., Zhong, D., Meng, M., Zhang, L., Chen, H., & Fang, L. (2024). Multi-omic profiling reveals associations between the gut microbiome, host genome and transcriptome in patients with colorectal cancer. Journal of Translational Medicine, 22(1), 175. https://doi.org/10.1186/s12967-024-04984-4
Zwezerijnen-Jiwa, F. H., Sivov, H., Paizs, P., Zafeiropoulou, K., & Kinross, J. (2023). A systematic review of microbiome-derived biomarkers for early colorectal cancer detection. Neoplasia, 36, 100868. https://doi.org/10.1016/j.neo.2022.100868
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Mateusz Sydor, Wojciech Plizga, Zuzanna Lepa, Aleksandra Bułat
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
